idrx.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $242.24MM
IDRx is a clinical-stage biopharmaceutical company committed to transforming cancer care with selective targeted combined therapies.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/07/2024 | Series B | $120.24MM | $xx.xx | $414.65MM | RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest | |
Price per Share
$xx.xx
Shares Outstanding
18,667,528
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest
|
||||||
08/02/2022 | Series A-2 | $16.19MM | $xx.xx | $309.5MM | Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines | |
Price per Share
$xx.xx
Shares Outstanding
2,947,184
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines
|
||||||
08/02/2022 | Series A-1 | $105.81MM | $xx.xx | $309.5MM | Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines | |
Price per Share
$xx.xx
Shares Outstanding
17,333,480
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines
|